low - Rare disease treatments for serious genetic disorders are medically necessary and non-discretionary. PWS patients require continuous management regardless of economic conditions. However, biotech sector valuations are cyclical and correlate with risk appetite, IPO markets, and broader healthcare spending trends. Economic downturns can pressure biotech stock multiples even when underlying business fundamentals are insulated.

Rising interest rates negatively impact Soleno through multiple channels: (1) Higher discount rates compress NPV of future cash flows, particularly punitive for pre-revenue companies with distant profitability; (2) Increases cost of capital for future financing needs, though company currently has strong cash position; (3) Risk-off sentiment in rate-hiking cycles reduces speculative capital flows to clinical-stage biotech; (4) Competition from risk-free rates makes high-risk biotech investments less attractive on relative basis. Rate cuts would provide valuation tailwind.

growth/speculative - Attracts biotech-focused investors, event-driven hedge funds playing binary FDA catalysts, and rare disease specialists. High-risk/high-reward profile appeals to investors comfortable with clinical-stage volatility and regulatory uncertainty. Not suitable for income or value investors given zero revenue, negative cash flow, and absence of dividends. Requires conviction in PWS market opportunity and DCCR clinical profile. Typical holders include biotech-dedicated funds, crossover healthcare investors, and momentum traders around regulatory catalysts.